Angiopoietin-2 (Ang-2) is a protein in the body which destabilizes blood vessels and is important in stimulating tumor blood vessels. There is evidence suggesting that Ang-2 may be important for the growth and progression of Glioblastoma multiforme (GBM). PF- 04856884 (CVX-060) is a compound which binds Ang-2 and prevents its activity. The hypothesis is that PF-04856884 will be safe and effective in patients with recurrent Glioblastoma multiforme (GBM).

Notification of study being cancelled resulted in update in overall status change from "not yet recruiting" to "withdrawn."

Inclusion Criteria:

• Tumor eligibility: Primary Cohort: Measurable disease; Exploratory Cohort: Measurable disease as defined above or non-measurable/evaluable disease (eg, progressing non-enhancing lesions).
• Histologically or cytologically confirmed recurrent GBM in 1st or 2nd relapse: Primary Cohort: Recurrence following radiation therapy and temozolomide, less than or equal to 2 prior chemotherapeutic regimens; Exploratory cohort: Prior radiation therapy, temozolomide, and bevacizumab, Recurrence of disease within 2-4 weeks of last bevacizumab dose.
• Stable dose of corticosteroids for greater than or equal to 5 days prior to baseline Magnetic Resonance Imaging (MRI)
• Adequate organ function
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Life expectancy greater than or equal to 12 weeks.

Exclusion Criteria:

• Patients who have previously received a trial drug containing the core platform antibody (eg, CVX-045, PF-04856884 (CVX-060), CVX-096, PF-05057459 (CVX-241), etc.).
• History of pathologic fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of therapy.
• Evidence of bleeding diathesis or coagulopathy.
• Major surgical procedure (eg, craniotomy), open biopsy, significant traumatic injury within 28 days prior to therapy or anticipation of need for a major surgical procedure during the course of the trial.
• Minor surgical procedures, fine needle aspiration or core biopsies within 7 days prior to therapy.
• Serious non-healing wound, ulcer, or bone fracture.
• Active gastrointestinal bleeding, as evidenced by either hematemesis, hematochezia, or melena in prior 6 months.
• Hemoptysis >½ teaspoon per day within 1 week of enrollment.
• National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI CTCAE] Grade 3 hemorrhage from any cause <4 weeks prior to enrollment.
• Participation in any investigational drug study within 28 days prior to study therapy.
• Evidence of preexisting uncontrolled hypertension
• Clinically significant cardiovascular disease within the 12 months prior to starting trial treatment
• Prolongation of the QT interval corrected [QTc] interval to >450 msec for men or >470 msec for women.
• History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.

Exclusion Criteria Specific for Primary Cohort

• Prior therapy with bevacizumab or other anti-Vascular Endothelial Growth Factor [VEGF] agents for the treatment of GBM.

Exclusion Criteria Specific for Exploratory Cohort

• Patients discontinued from prior bevacizumab or anti-VEGF agents due to toxicity.
• Patients who have failed 2 prior anti-VEGF therapies.